Advanced in AIDS Dementia Complex

Dr. Cornelius N. Van Dam

Infectious Disease
The Moses H Cone Memorial Hospital Operating Corporation
301 E Wendover Ave, Suite 111, 
Greensboro, NC 
Accepting New Patients
Offers Telehealth
Advanced in AIDS Dementia Complex
The Moses H Cone Memorial Hospital Operating Corporation
301 E Wendover Ave, Suite 111, 
Greensboro, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Cornelius Van Dam is an Infectious Disease provider in Greensboro, North Carolina. Dr. Van Dam is rated as an Advanced provider by MediFind in the treatment of AIDS Dementia Complex. His top areas of expertise are HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex. Dr. Van Dam is currently accepting new patients.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Medical College Of Wisconsin
Specialties
Infectious Disease
Licenses
Internal Medicine in NC
Hospital Affiliations
The Moses H. Cone Memorial Hospital
Languages Spoken
English
Dutch
French
German
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

THE MOSES H CONE MEMORIAL HOSPITAL OPERATING CORPORATION
301 E Wendover Ave, Suite 111, Greensboro, NC 27401

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Doravirine, Tenofovir alafenamide, Emtricitabine, Lamivudine, Integrase strand transfer inhibitors, Tenofovir disproxil fumarate
Study Phase: Phase 4
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: Glecaprevir+Pibrentasvir, Ribavirin
Study Phase: Phase 2
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)
Enrollment Status: Completed
Publish Date: June 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

13 Total Publications

Risks for sudden cardiac and undetermined cause of death among people with HIV in the reprieve primary cardiovascular prevention trial.
Risks for sudden cardiac and undetermined cause of death among people with HIV in the reprieve primary cardiovascular prevention trial.
Journal: AIDS (London, England)
Published: March 04, 2025
Similar Doctors
Distinguished in AIDS Dementia Complex
Dr. Aimee M. Wilkin
Infectious Disease
Distinguished in AIDS Dementia Complex
Dr. Aimee M. Wilkin
Infectious Disease

Wake Forest University Health Sciences

Medical Ctr Blvd, 
Winston Salem, NC 
 (27.1 miles away)
336-716-2734
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Aimee Wilkin is an Infectious Disease provider in Winston Salem, North Carolina. Dr. Wilkin is rated as a Distinguished provider by MediFind in the treatment of AIDS Dementia Complex. Her top areas of expertise are HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex. Dr. Wilkin is currently accepting new patients.

Distinguished in AIDS Dementia Complex
Dr. Jeffrey C. Hatcher
Infectious Disease
Distinguished in AIDS Dementia Complex
Dr. Jeffrey C. Hatcher
Infectious Disease

The Moses H Cone Memorial Hospital Operating Corporation

1200 N Elm St, 
Greensboro, NC 
 (0.3 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Hatcher is an Infectious Disease provider in Greensboro, North Carolina. Dr. Hatcher is rated as an Advanced provider by MediFind in the treatment of AIDS Dementia Complex. His top areas of expertise are Myelitis, HIV/AIDS, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex. Dr. Hatcher is currently accepting new patients.

Joseph J. Eron
Distinguished in AIDS Dementia Complex
Dr. Joseph J. Eron
Infectious Disease
Distinguished in AIDS Dementia Complex
Dr. Joseph J. Eron
Infectious Disease

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (42.9 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Eron is an Infectious Disease provider in Chapel Hill, North Carolina. Dr. Eron is rated as a Distinguished provider by MediFind in the treatment of AIDS Dementia Complex. His top areas of expertise are HIV/AIDS, AIDS Dysmorphic Syndrome, AIDS Dementia Complex, Myelitis, and Tissue Biopsy. Dr. Eron is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Van Dam's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile